Catheter Precision, Inc. Announces First Purchase Order From University Hospital in Rennes, France

Rhea-AI Summary

Catheter Precision (NYSE:VTAK) has secured its largest purchase order to date for its VIVO product line from Centre Hospitalier Universitaire (CHU) de Rennes in France. The hospital, which serves approximately 500,000 patients annually, performs over 150 ventricular ablations per year, making it one of Europe's largest ventricular ablation centers.

CEO David Jenkins emphasized the strategic importance of partnering with teaching hospitals to introduce their products to physicians early in their careers, which could lead to long-term product adoption.

Positive

• Secured largest VIVO product line purchase order to date
• Partnership with one of Europe's largest ventricular ablation centers (150+ VA procedures/year)
• Strategic entry into teaching hospital environment for long-term physician adoption

Negative

• None.

FORT MILL, S.C., July 07, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced today that it has received a purchase order from Centre Hospitalier Universitaire (CHU) de Rennes. This is the first purchase order from Universite de Rennes and marks the largest purchase order for the VIVO product line to date.

CHU Rennes serves almost 500,000 patients annually with a mission of teaching, research and innovation.

David Jenkins, CEO of Catheter Precision, said, “We are very pleased to add CHU Rennes to our growing list of customers. We understand that the hospital performs over 150 ventricular ablations (VA) per year, which makes it one of the largest ventricular ablation centers not just in France, but in all of Europe. Introducing our products to new physicians at teaching hospitals is a key to expanding our user base as it introduces our products early in their careers, increasing the likelihood of long-term product adoption.”

About VIVO™
Catheter Precision’s VIVO (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE Mark.

About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.

Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “may,” “seek,” or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words.  These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring and expectations regarding LockeT evaluations in the coming weeks. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption “Risk Factors” in the Company’s Form 10-K filed with the SEC and available at www.sec.gov.

The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

CONTACTS:

Investor Relations
973-691-2000
IR@catheterprecision.com

# # #

FAQ

What is the significance of Catheter Precision's (VTAK) purchase order from CHU Rennes?

It represents the largest purchase order for VTAK's VIVO product line to date, from one of Europe's largest ventricular ablation centers.

How many ventricular ablations does CHU Rennes perform annually?

CHU Rennes performs over 150 ventricular ablations per year, making it one of the largest ventricular ablation centers in Europe.

How many patients does Centre Hospitalier Universitaire de Rennes serve annually?

CHU Rennes serves approximately 500,000 patients annually with a focus on teaching, research and innovation.

Why is CHU Rennes significant for Catheter Precision's (VTAK) market strategy?

As a teaching hospital, it allows VTAK to introduce products to physicians early in their careers, increasing the likelihood of long-term product adoption.